Cell therapies administered in the chronic phase after stroke: a meta-analysis examining safety and efficacy
Date
2017
Authors
Unsworth, D.
Mathias, J.
Dorstyn, D.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Regenerative Medicine, 2017; 12(1):91-108
Statement of Responsibility
David J Unsworth, Jane L Mathias, Diana S Dorstyn
Conference Name
Abstract
AIM: To assess the safety and efficacy of cell therapies for chronic stroke. METHODOLOGY: Five databases were searched for treatments administered >90 days post-stroke. Reporting quality, adherence to research guidelines, treatment safety (risk ratios/pooled incidence rates) and neurological/functional efficacy (Hedge's g) were all evaluated. RESULTS: Twenty-three studies examined 17 treatments. Reporting quality scores were medium to high, but adherence to recommended guidelines was lower. Three treatments resulted in serious adverse events; four improved outcomes more than standard care. However, many studies were under-powered and individual patients varied in their response to some treatments. CONCLUSION: Preliminary findings suggest that some cell therapies may be relatively safe and effective, but larger double-blinded placebo-controlled studies are needed to establish the long-term risks and benefits.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© Future Medicine Ltd.